S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
This Stock Could Go Up 66% or More. (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
This Stock Could Go Up 66% or More. (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
This Stock Could Go Up 66% or More. (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
This Stock Could Go Up 66% or More. (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
This Stock Could Go Up 66% or More. (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
This Stock Could Go Up 66% or More. (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
This Stock Could Go Up 66% or More. (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
This Stock Could Go Up 66% or More. (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
NASDAQ:CDMO

Avid Bioservices (CDMO) Stock Forecast, Price & News

$9.44
-0.28 (-2.88%)
(As of 09/29/2023 ET)
Compare
Today's Range
$9.42
$9.87
50-Day Range
$9.40
$13.32
52-Week Range
$9.18
$21.05
Volume
486,572 shs
Average Volume
702,686 shs
Market Capitalization
$595.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.00

Avid Bioservices MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
111.9% Upside
$20.00 Price Target
Short Interest
Bearish
8.38% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.96
Upright™ Environmental Score
News Sentiment
0.89mentions of Avid Bioservices in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$394,626 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.14) to $0.13 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

458th out of 972 stocks

Pharmaceutical Preparations Industry

203rd out of 452 stocks


CDMO stock logo

About Avid Bioservices (NASDAQ:CDMO) Stock

Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services of biologics for the biotechnology and biopharmaceutical industries. The company offers various services, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.

CDMO Price History

CDMO Stock News Headlines

Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
Q1 2024 Avid Bioservices Inc Earnings Call
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
Earnings Outlook For Avid Bioservices
Why Avid Bioservices Stock Was Plummeting This Week
Avid Bioservices FQ4 2023 Earnings Preview
Should You Invest in Avid Bioservices (CDMO)?
See More Headlines
Receive CDMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avid Bioservices and its competitors with MarketBeat's FREE daily newsletter.

CDMO Company Calendar

Last Earnings
9/07/2023
Today
9/30/2023
Next Earnings (Estimated)
12/05/2023
Fiscal Year End
4/30/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CDMO
Employees
365
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$20.00
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+111.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$560,000.00
Pretax Margin
-1.96%

Debt

Sales & Book Value

Annual Sales
$149.27 million
Cash Flow
$0.15 per share
Book Value
$3.02 per share

Miscellaneous

Free Float
61,605,000
Market Cap
$595.76 million
Optionable
Optionable
Beta
1.68
10 Best Stocks to Own in 2023 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Nicholas Stewart Green B.Sc.Mr. Nicholas Stewart Green B.Sc. (Age 58)
    MBA, Pres, CEO & Director
    Comp: $1.35M
  • Mr. Daniel R. HartMr. Daniel R. Hart (Age 50)
    Chief Financial Officer
    Comp: $719.75k
  • Mr. Richard Richieri (Age 58)
    Chief Operations Officer
    Comp: $561.68k
  • Mr. Mark R. Ziebell J.D.Mr. Mark R. Ziebell J.D. (Age 59)
    VP, Gen. Counsel & Corp. Sec.
    Comp: $647.1k
  • Mr. Matthew Kwietniak (Age 54)
    Chief Commercial Officer
    Comp: $553.59k
  • Ms. Oksana Lukash
    VP of People













CDMO Stock - Frequently Asked Questions

Should I buy or sell Avid Bioservices stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Avid Bioservices in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CDMO shares.
View CDMO analyst ratings
or view top-rated stocks.

What is Avid Bioservices' stock price forecast for 2023?

3 brokerages have issued 12-month price objectives for Avid Bioservices' shares. Their CDMO share price forecasts range from $15.00 to $25.00. On average, they anticipate the company's stock price to reach $20.00 in the next twelve months. This suggests a possible upside of 111.9% from the stock's current price.
View analysts price targets for CDMO
or view top-rated stocks among Wall Street analysts.

How have CDMO shares performed in 2023?

Avid Bioservices' stock was trading at $13.77 at the beginning of 2023. Since then, CDMO stock has decreased by 31.4% and is now trading at $9.44.
View the best growth stocks for 2023 here
.

When is Avid Bioservices' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, December 5th 2023.
View our CDMO earnings forecast
.

How were Avid Bioservices' earnings last quarter?

Avid Bioservices, Inc. (NASDAQ:CDMO) announced its quarterly earnings results on Thursday, September, 7th. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.01. The biopharmaceutical company earned $37.73 million during the quarter, compared to the consensus estimate of $34 million. Avid Bioservices had a negative net margin of 2.06% and a negative trailing twelve-month return on equity of 1.54%. During the same period in the prior year, the business earned $0.02 EPS.

What ETFs hold Avid Bioservices' stock?

ETFs with the largest weight of Avid Bioservices (NASDAQ:CDMO) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE) and Franklin Genomic Advancements ETF (HELX).Invesco S&P SmallCap Health Care ETF (PSCH).

When did Avid Bioservices' stock split?

Avid Bioservices shares reverse split on Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 7th 2017. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

What guidance has Avid Bioservices issued on next quarter's earnings?

Avid Bioservices updated its FY 2024 earnings guidance on Thursday, September, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $145.00 million-$165.00 million, compared to the consensus revenue estimate of $155.71 million.

What is Roger Lias' approval rating as Avid Bioservices' CEO?

5 employees have rated Avid Bioservices Chief Executive Officer Roger Lias on Glassdoor.com. Roger Lias has an approval rating of 49% among the company's employees. This puts Roger Lias in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 63.0% of employees surveyed would recommend working at Avid Bioservices to a friend.

What other stocks do shareholders of Avid Bioservices own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avid Bioservices investors own include Array Technologies (ARRY), Anavex Life Sciences (AVXL), Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Micron Technology (MU), QUALCOMM (QCOM), NVIDIA (NVDA), Novavax (NVAX) and Pfizer (PFE).

What is Avid Bioservices' stock symbol?

Avid Bioservices trades on the NASDAQ under the ticker symbol "CDMO."

How do I buy shares of Avid Bioservices?

Shares of CDMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avid Bioservices' stock price today?

One share of CDMO stock can currently be purchased for approximately $9.44.

How much money does Avid Bioservices make?

Avid Bioservices (NASDAQ:CDMO) has a market capitalization of $595.76 million and generates $149.27 million in revenue each year. The biopharmaceutical company earns $560,000.00 in net income (profit) each year or ($0.04) on an earnings per share basis.

How many employees does Avid Bioservices have?

The company employs 365 workers across the globe.

How can I contact Avid Bioservices?

Avid Bioservices' mailing address is 2642 Michelle Drive Suite 200, TUSTIN CA, 92780. The official website for the company is www.avidbio.com. The biopharmaceutical company can be reached via phone at (714) 508-6100, via email at sdiaz@vidasp.com, or via fax at 714-838-5817.

This page (NASDAQ:CDMO) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -